You just read:

LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union

News provided by

LEO Pharma A/S

20 Jul, 2017, 08:00 BST